CDKN2A and colorectal carcinoma: The remaining approximate 25% of CRC patients carrying BRAFV600E mutation showed a high level of CDKN2A (p16) promoter methylation along with a high level of CIMP without MLH-1 promoter methylation indicating microsatellite stability (MSS) [2].